Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire remaining 40% stake in Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology (Dali) Co., Ltd. from Zhou Zhenke for CNY 0.15 million on April 27, 2023. Transaction has been approved by Hybio Pharmaceutical's board. For the period March 31, 2023, Shenzhen Huaxiang Zhiyuan had CNY 3.43953562 million of total assets and CNY 3.3942402 million of Net assets.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 CNY | +0.70% |
|
-6.39% | -25.63% |
Jul. 05 | Hybio Pharmaceutical Secures Chilean Medical Approval for Injectable Medication | MT |
Jul. 02 | Hybio Pharmaceutical Unit's Bone Disease Drug Gets China Marketing Nod | MT |
1st Jan change | Capi. | |
---|---|---|
-25.63% | 1.23B | |
+26.92% | 45.55B | |
+33.33% | 23.65B | |
+25.28% | 16.22B | |
+21.42% | 14.62B | |
+71.23% | 14.04B | |
-13.71% | 6.36B | |
-8.87% | 5.73B | |
+15.70% | 5.77B | |
+12.06% | 4.8B |
- Stock Market
- Equities
- 300199 Stock
- News Hybio Pharmaceutical Co., Ltd.
- Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.